FDA approves landmark pancreatic cancer drug that's shown to improve survival

The FDA approved a pancreatic cancer drug that blocks a protein involved in tumor growth. The medication targets a protein present in the majority of pancreatic cancer cases. Clinical trial data showed improved survival outcomes, though specific survival figures were not provided in the available information.

Next story